Transcriptional Switch of Dormant Tumors to Fast-Growing Angiogenic Phenotype

¹Center of Cancer Systems Biology, Caritas St. Elizabeth's Medical Center, Tufts University School of Medicine; ²Vascular Biology Program, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts; ³Department of Radiation Oncology, German Cancer Research Center (DKFZ) and University of Heidelberg Medical School, Heidelberg, Germany; and ⁴Department of Neurosurgery, Charité-Universitaetsmedizin Berlin, Berlin, Germany

^* To whom correspondence should be addressed. E-mail: Amir.Abdollahi{at}Tufts.edu.

	Abstract

Tumor dormancy has important implications for early detection and treatment of cancer. Lack of experimental models and limited clinical accessibility constitute major obstacles to the molecular characterization of dormant tumors. We have developed models in which human tumors remain dormant for a prolonged period of time (>120 days) until they switch to rapid growth and become strongly angiogenic. These angiogenic tumors retain their ability to grow fast once injected in new mice. We hypothesized that dormant tumors undergo a stable genetic reprogramming during their switch to the fast-growing phenotype. Genome-wide transcriptional analysis was done to dissect the molecular mechanisms underlying the switch of dormant breast carcinoma, glioblastoma, osteosarcoma, and liposarcoma tumors. A consensus expression signature distinguishing all four dormant versus switched fast-growing tumors was generated. In alignment with our phenotypic observation, the angiogenesis process was the most significantly affected functional gene category. The switch of dormant tumors was associated with down-regulation of angiogenesis inhibitor thrombospondin and decreased sensitivity of angiogenic tumors to angiostatin. The conversion of dormant tumors to exponentially growing tumors was also correlated with regulation and activation of pathways not hitherto linked to tumor dormancy process, such as endothelial cell–specific molecule-1, 5'-ecto-nucleotidase, tissue inhibitor of metalloproteinase-3, epidermal growth factor receptor, insulin-like growth factor receptor, and phosphatidylinositol 3-kinase signaling. Further, novel dormancy-specific biomarkers such as H2BK and Eph receptor A5 (EphA5) were discovered. EphA5 plasma levels in mice and mRNA levels in tumor specimens of glioma patients correlated with diseases stage. These data will be instrumental in identifying novel early cancer biomarkers and could provide a rationale for development of dormancy-promoting tumor therapy strategies. [Cancer Res 2009;69(3):836–44]

Key Words: Tumor dormancy, angiogenesis, gene profiling

This article has been cited by other articles:

				H. Laklai, S. Laval, L. Dumartin, P. Rochaix, M. Hagedorn, A. Bikfalvi, S. Le Guellec, M.-B. Delisle, A. V. Schally, C. Susini, et al. Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer PNAS, October 20, 2009; 106(42): 17769 - 17774. [Abstract] [Full Text] [PDF]